HMG-CoA reductase inhibitors may affect thrombin generation by reducing factor VII activity in hyperlipidemic patients.
Ural
A Ugur
AU
Avcu
Ferit
F
D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000494:pharmacology* / Q000627:therapeutic use; D000069059:Atorvastatin; D015331:Cohort Studies; D003327:Coronary Disease / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006538:Heptanoic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D006949:Hyperlipidemias / Q000188:drug therapy / Q000378:metabolism*; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011516:Prothrombin / Q000378:metabolism; D011758:Pyrroles / Q000008:administration & dosage / Q000627:therapeutic use; D013917:Thrombin / Q000096:biosynthesis* / Q000187:drug effects; D013925:Thromboplastin / Q000187:drug effects / Q000378:metabolism*; D016896:Treatment Outcome
D000925:Anticoagulants; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D008074:Lipoproteins; D011758:Pyrroles; C051928:lipoprotein-associated coagulation inhibitor; D011516:Prothrombin; D013925:Thromboplastin; D000069059:Atorvastatin; D013917:Thrombin